Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-16
DOI
10.3389/fphar.2021.613211
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cellular Senescence in Neurodegenerative Diseases
- (2020) Carmen Martínez-Cué et al. Frontiers in Cellular Neuroscience
- Down syndrome
- (2020) Stylianos E. Antonarakis et al. Nature Reviews Disease Primers
- Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease
- (2019) Elena P. Moreno-Jiménez et al. NATURE MEDICINE
- Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARγ/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats
- (2019) Yuchun Zuo et al. Journal of Neuroinflammation
- Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome
- (2019) Alba Navarro-Romero et al. NEUROBIOLOGY OF DISEASE
- Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer’s Disease iPSC-Derived Neural Stem Cells
- (2019) Patricia Martín-Maestro et al. MOLECULAR NEUROBIOLOGY
- Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome
- (2019) Fiorenza Stagni et al. NEUROBIOLOGY OF DISEASE
- Pharmacotherapy of Down’s syndrome: When and Which?
- (2019) Seyed Khosrow Tayebati et al. CNS & Neurological Disorders-Drug Targets
- Bexarotene Attenuates Focal Cerebral Ischemia–Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway
- (2019) Hailin Liu et al. NEUROCHEMICAL RESEARCH
- Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer´s disease
- (2019) Jonathan Mauricio Muñoz-Cabrera et al. PLoS One
- Bexarotene treatment increases dendritic length in the nucleus accumbens without change in the locomotor activity and memory behaviors, in old mice
- (2019) Elibeth Monroy et al. JOURNAL OF CHEMICAL NEUROANATOMY
- Bexarotene Enhances Macrophage Erythrophagocytosis and Hematoma Clearance in Experimental Intracerebral Hemorrhage
- (2019) Che-Feng Chang et al. STROKE
- Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice
- (2018) Noemí Rueda et al. BRAIN BEHAVIOR AND IMMUNITY
- Neurogenesis impairment: An early developmental defect in Down syndrome
- (2018) Fiorenza Stagni et al. FREE RADICAL BIOLOGY AND MEDICINE
- OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice
- (2018) Chunling Yuan et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS
- (2017) Fiorenza Stagni et al. EXPERIMENTAL NEUROLOGY
- Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome
- (2017) Verónica Vidal et al. MOLECULAR NEUROBIOLOGY
- IL-17A Promotes Granulocyte Infiltration, Myelin Loss, Microglia Activation, and Behavioral Deficits During Cuprizone-Induced Demyelination
- (2017) Julian Zimmermann et al. MOLECULAR NEUROBIOLOGY
- Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes
- (2017) Susana García-Cerro et al. NEUROBIOLOGY OF DISEASE
- PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis
- (2017) Audrey S. Dickey et al. Science Translational Medicine
- Endocrine manifestations of Down syndrome
- (2017) Rachel Whooten et al. Current Opinion in Endocrinology Diabetes and Obesity
- Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1
- (2016) Masaya Tachibana et al. EXPERIMENTAL NEUROLOGY
- Retinoids and motor neuron disease: Potential role in amyotrophic lateral sclerosis
- (2016) Javier Riancho et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Mouse models of Down syndrome: gene content and consequences
- (2016) Meenal Gupta et al. MAMMALIAN GENOME
- Lack of support for bexarotene as a treatment for Alzheimer's disease
- (2016) Eugene O'Hare et al. NEUROPHARMACOLOGY
- Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome
- (2016) Fiorenza Stagni et al. NEUROSCIENCE
- Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease
- (2016) Jeffrey L. Cummings et al. Alzheimers Research & Therapy
- RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment
- (2015) Iliya Lefterov et al. NEUROBIOLOGY OF DISEASE
- Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice
- (2015) Fiorenza Stagni et al. NEUROBIOLOGY OF DISEASE
- Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke
- (2015) Michelangelo Certo et al. PHARMACOLOGICAL RESEARCH
- Chemopreventive Effects of RXR-Selective Rexinoid Bexarotene on Intestinal Neoplasia of ApcMin/+ Mice
- (2015) Naveena B. Janakiram et al. NEOPLASIA
- Nuclear Receptors, RXR, and the Big Bang
- (2014) Ronald M. Evans et al. CELL
- Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway
- (2014) Jing Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Reversal of apoE4-Driven Brain Pathology and Behavioral Deficits by Bexarotene
- (2014) A. Boehm-Cagan et al. JOURNAL OF NEUROSCIENCE
- Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy
- (2014) Valerie Bomben et al. NEUROBIOLOGY OF AGING
- Retinoids as potential targets for Alzheimer's disease
- (2014) Rupinder K. Sodhi et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations
- (2014) Katheleen Gardiner Drug Design Development and Therapy
- Low Dose Bexarotene Treatment Rescues Dopamine Neurons and Restores Behavioral Function in Models of Parkinson’s Disease
- (2013) Krista McFarland et al. ACS Chemical Neuroscience
- Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model
- (2013) Sandra Guidi et al. BRAIN
- Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21
- (2013) Youssef Hibaoui et al. EMBO Molecular Medicine
- Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis
- (2013) Donna M Wilcock et al. Journal of Neuroinflammation
- Reducing GABAA 5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome
- (2013) C. Martinez-Cue et al. JOURNAL OF NEUROSCIENCE
- Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome
- (2013) Andrea Corrales et al. JOURNAL OF PINEAL RESEARCH
- Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
- (2013) Chia-Chen Liu et al. Nature Reviews Neurology
- Response to Comments on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"
- (2013) G. E. Landreth et al. SCIENCE
- Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"
- (2013) N. F. Fitz et al. SCIENCE
- Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"
- (2013) I. Tesseur et al. SCIENCE
- Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"
- (2013) K. Veeraraghavalu et al. SCIENCE
- Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"
- (2013) A. R. Price et al. SCIENCE
- Cytokine and Chemokine Alterations in Down Syndrome
- (2012) Robin Roberson et al. AMERICAN JOURNAL OF PERINATOLOGY
- Alzheimer Mechanisms and Therapeutic Strategies
- (2012) Yadong Huang et al. CELL
- Regulation of CCL20 expression in astrocytes by IL-6 and IL-17
- (2012) Gordon P. Meares et al. GLIA
- Lithium rescues synaptic plasticity and memory in Down syndrome mice
- (2012) Andrea Contestabile et al. JOURNAL OF CLINICAL INVESTIGATION
- Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome
- (2012) Andrea Corrales et al. JOURNAL OF PINEAL RESEARCH
- The Ethics of Early Evidence — Preparing for a Possible Breakthrough in Alzheimer's Disease
- (2012) Justin Lowenthal et al. NEW ENGLAND JOURNAL OF MEDICINE
- ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models
- (2012) P. E. Cramer et al. SCIENCE
- Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities
- (2012) Noemí Rueda et al. NEURAL PLASTICITY
- Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-β in a Patient With Down Syndrome and Alzheimer Disease
- (2011) Marwan N. Sabbagh ARCHIVES OF NEUROLOGY
- Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome
- (2011) Giovanna Cenini et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Neurobiological Elements of Cognitive Dysfunction in Down Syndrome: Exploring the Role of APP
- (2011) Martha Millan Sanchez et al. BIOLOGICAL PSYCHIATRY
- Nuclear receptors as therapeutic targets for Alzheimer's disease
- (2011) Shweta Mandrekar-Colucci et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome
- (2011) Mototada Shichiri et al. FREE RADICAL BIOLOGY AND MEDICINE
- Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions
- (2011) Xiaolu Sturgeon et al. MAMMALIAN GENOME
- Is it possible to improve neurodevelopmental abnormalities in Down syndrome?
- (2011) Renata Bartesaghi et al. REVIEWS IN THE NEUROSCIENCES
- Trisomy 21 and early brain development
- (2011) Tarik F. Haydar et al. TRENDS IN NEUROSCIENCES
- Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome
- (2010) Jason Lockrow et al. BEHAVIOURAL BRAIN RESEARCH
- Liver X Receptor Agonist Treatment Ameliorates Amyloid Pathology and Memory Deficits Caused by High-Fat Diet in APP23 Mice
- (2010) N. F. Fitz et al. JOURNAL OF NEUROSCIENCE
- Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome
- (2010) P. Bianchi et al. JOURNAL OF NEUROSCIENCE
- Lowering β-Amyloid Levels Rescues Learning and Memory in a Down Syndrome Mouse Model
- (2010) William J. Netzer et al. PLoS One
- IL-17 and Th17 Cells
- (2009) Thomas Korn et al. Annual Review of Immunology
- Lithium Restores Neurogenesis in the Subventricular Zone of the Ts65Dn Mouse, a Model for Down Syndrome
- (2009) Patrizia Bianchi et al. BRAIN PATHOLOGY
- Targeting Aβ and tau in Alzheimer's disease, an early interim report
- (2009) Todd E. Golde et al. EXPERIMENTAL NEUROLOGY
- Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
- (2009) Guojun Bu NATURE REVIEWS NEUROSCIENCE
- Working memory deficits in healthy APOE epsilon 4 carriers
- (2009) Ivar Reinvang et al. NEUROPSYCHOLOGIA
- Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model
- (2008) Jason Lockrow et al. EXPERIMENTAL NEUROLOGY
- RXR agonists inhibit high-glucose-induced oxidative stress by repressing PKC activity in human endothelial cells
- (2008) Dajun Chai et al. FREE RADICAL BIOLOGY AND MEDICINE
- Impact of APOE status on cognitive maintenance in healthy elderly persons
- (2008) Antoinette E. Zehnder et al. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
- ApoE Promotes the Proteolytic Degradation of Aβ
- (2008) Qingguang Jiang et al. NEURON
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started